Roche Diagnostics and FIND sign agreement of collaboration in diagnostics for poverty-related diseases
Roche Applied Science, a business area of Roche Diagnostics, and the Foundation for Innovative New diagnostics (FIND) have signed a Letter of Intent to further explore possibilities for the development or support of projects in the area of in-vitro diagnostics (IVD) products for poverty-related diseases.
FIND and Roche Diagnostics agreed to evaluate several fields of collaboration of common interest, to evaluate possibilities for introduction of new diagnostic tools in the public health sector of high endemic countries. Among other aspects of this collaboration, FIND will be responsible for conducting studies for the technical product evaluation in relevant clinical settings in developing countries. Roche will bring in their experience in development and service in diagnostics.
Most read news
Organizations
Other news from the department business & finance

Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.